Wednesday, May 27, 2015 6:19:59 AM
Research Associate Intern
Employee Type: Paid Internship; hours will vary between 20-40 hours per week
Location: Inovio Pharmaceuticals, Inc.
San Diego, CA Office - 11494 Sorrento Valley Road, San Diego, CA 92121
Reports to: Plasmid Production Scientist
Job Description:
We are currently expanding our research and development efforts and seeking a temporary (with the possibility of becoming full-time) Research Associate I Intern with a background in immunology, molecular or cell biology. The ideal candidate will not only meet the minimum and essential requirements, but can also work independently, solve complex problems, and master a spectrum of techniques in both basic cell and molecular biology and immunology including cell cultures and DNA preps.
Essential Job Functions:
DNA Purification
Gel Electrophoresis
Cell Cultures
Histology, IHC
Assist with ELiSA assays
Assist with animal experiments
Blood and tissue sampling
Present experimental results in departmental and/or company meetings
Adhere to corporate policies and SOPs
General lab duties such as reagents prep, stocking of supplies, cleaning, shipping and receiving
Documentation and record keeping
Drive between different work locations within San Diego
Minimum Requirements:
BS or currently a college senior in the biological sciences, preferably in immunology, cell or molecular biology, or bioengineering
Laboratory knowledge
Essential Requirements:
Experience in aseptic/GLP techniquess
Willingness to work with animals; experience in animal handling a plus
Attention to detail, ability to prioritize and handle multiple projects
Proficiency in MS Office applications
Excellent organizational and written/oral communication skills
The above statements are intended to describe the general nature and level of work being performed by people assigned to this classification. They are not to be construed as an exhaustive list of all responsibilities, duties, and skills required of personnel so classified. All personnel may be required to perform duties outside of their normal responsibilities from time to time, as needed. Inovio offers an attractive benefits package and is an equal opportunity employer.
Inovio Pharmaceuticals offers an attractive benefits package and is an Equal Opportunity Employer. Current US work authorization is required.
For consideration, please send your resume and a concise cover letter describing your qualifications to: careers@inovio.com with “SD RA I Intern” in the subject line.
http://www.inovio.com/company/careers/research-associate-i-intern/
=======================================
Developmental scale-up for new biopharmaceuticals
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM